In adults aged 75 and older without prior cardiovascular disease who were taking statins for primary prevention, stopping statins proved non-inferior to continuing them for all-cause mortality over three years. This challenges the routine continuation of statins in this population and supports reassessment of preventive medication in advanced age.
Key Points
- Statin discontinuation non-inferior to continuation for mortality in adults 75+
- Population had no prior cardiovascular disease history
- Three-year follow-up period; all-cause mortality endpoint
Longevity Analysis
The relationship between medication burden and aging physiology is underexplored in prevention strategies. As the body ages, its capacity to metabolize and tolerate medications changes, yet preventive regimens designed for younger populations often persist unchanged. This trial demonstrates that for older adults without existing cardiovascular disease, the risk-benefit calculus of statin therapy shifts substantially. Reducing unnecessary pharmaceutical load may decrease interference with the body's regulatory systems while preserving outcomes — a principle that extends beyond statins to how we approach pharmaceutical prevention in advanced age.
Original published by The Lancet Healthy Longevity, by Fabrice Bonnet, Pierre Poulizac, Nicolas Rousselot, Thierry Couffinhal, Gaël Galli, Driss Berdaï, Marie-Anne Vandenhende, Marine Rousset, Roxane Coueron, Antoine Bénard, Jean-Philippe Joseph, The SAGA/SITE Study Group.